Hims & Hers Health, Inc. (HIMS)
Hims & Hers Health: The Real Story Begins
Hims & Hers Health raised FY2026 revenue guidance to $2.8-$3.0 billion despite reporting a heavily distorted quarterly EPS loss. More than 125,000 Wegovy shipments in six weeks suggest Novo conversion rates are materially outperforming bearish expectations. Gross margin fell to 65%, but adjusted gross margin exceeded 70% after excluding $33 million in restructuring charges.
Hims & Hers Stock Plunges Post Q1 Earnings Miss, Gross Margin Down
HIMS reports an adjusted loss and a revenue miss in first-quarter 2026 as gross margin decreases, but it lifts its full-year revenue outlook.
Hims & Hers shares plummet on first quarter earnings miss
Hims & Hers (NYSE:HIMS) reported first quarter financial results that included a wider-than-expected loss and softer revenue performance, sending shares down nearly 14% to about $25 on Tuesday morning. For the quarter, the telehealth company posted a net loss of $92.1 million, or $0.40 loss per share, compared with a net profit of $49.5 million in the same period last year.
Hims & Hers: I See No New Red Flags
Hims & Hers stock is crashing in pre-market trading, down about 14%, after reporting a disastrous Q1 and an upbeat Q2 outlook. We don't find Q1 weakness surprising due to the Novo deal timing and tough Y/Y comparison with 1Q25. We understand that investors wanted more from print after the stock doubled from $14 lows, but we remain confident that, post-expectation reset, HIMS will be better positioned to beat expectations.
U.S.-Iran Ceasefire on "Life Support," HIMS & ASTS Earnings Sell-Off
The U.S.-Iran ceasefire is on "life support," according to President Trump, causing stocks to slide and crude oil to climb in the overnight hours. Kevin Green explains how the geopolitical headlines come head-to-head with the red-hot tech rally.
Hims & Hers Health, Inc. (HIMS) Q1 2026 Earnings Call Transcript
Hims & Hers Health, Inc. (HIMS) Q1 2026 Earnings Call Transcript
Hims & Hers Health Q1 Earnings Call Highlights
Hims & Hers Health NYSE: HIMS reported first-quarter 2026 revenue growth and raised its full-year revenue outlook, while executives said a strategic shift in the company's weight-loss business is creating short-term margin pressure and volatility in GAAP results.
Hims & Hers Health: Mixed Q1 2026 Is Not A Thesis Breaker
Hims & Hers Health, Inc. remains a Buy, with a solid bottom forming despite recent margin and revenue challenges. HIMS is pivoting from compounded GLP-1s to branded partnerships with NVO and LLY, impacting near-term margins but reducing legal risk. Q1 2026 saw revenue miss and margin compression, but management raised full-year revenue guidance and expects margin expansion in H2.
Hims & Hers Health, Inc. (HIMS) Reports Q1 Loss, Misses Revenue Estimates
Hims & Hers Health, Inc. (HIMS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of $0.04. This compares to earnings of $0.2 per share a year ago.
Hims & Hers Stock Sinks. Why Earnings Offered Wall Street A Big Surprise.
Hims & Hers shares are falling after reporting disappointing first-quarter earnings results.
Can Platform Expansion Support Hims & Hers Stock Before Q1 Earnings?
HIMS first-quarter 2026 results are likely to benefit from Labs and branded weight loss medications even as higher costs and GLP-1 scrutiny linger.
Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note
Hims & Hers Health, Inc. (HIMS) closed at $26.37 in the latest trading session, marking a -3.79% move from the prior day.
